Search for a command to run...
No recent news available for this stock.
Conference call summary is not available for this stock.
Morepen Laboratories Ltd. shows moderate growth and strong financial health compared to its peers. While it has the lowest debt levels, its profitability metrics are lower than those of top performers in the sector. Companies like Cipla and Dr. Reddy's Laboratories exhibit superior profitability and growth, positioning them as sector leaders, while Divi's Laboratories and Sun Pharmaceutical Industries appear overvalued given their high PE ratios.
Highest ROE (16.63%) and significant revenue growth (YoY 13.28%).
Strong profitability with an ROE of 21.76% and high growth trajectory.
Outstanding revenue growth of 18.12% YoY and strong profitability metrics.